Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.01

-2.9%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Louis A. Rawden who wrote (27394)	1/14/1999 7:49:00 AM
From: Henry Niman	Read Replies (1) of 32384

Louis, I think that many investors are taking a look at Biotechs, so if you have a question, you can be fairly certain that many more would also like more info. For clinical trials, the three Phases are divided up to provide info for a NDA (New drug Application) and results from one phase are used to design the trial for the next phase. Phase I is designed to see if the compound is safe in humans (and a fair amount of animal is a prerequisite for the start of a Phase I trial). If the compound is safe, then Phase II trials are designed to determine the optimal concentration. Phase III is designed to used the optimal concentration on a larger population. If the data is very positive in Phase III (as it was in the International topical trial for Panretin), then the company may elect to halt the trial because they have enough data to submit in their NDA application, and it would be unethical to continue to treat patients with the inferior treatment (for Panretin the control arm received a placebo, but sometimes the control gets the gold standard).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next